Chemical Structure (Gemcitabine 01)
Gemcitabine Injection, Solution
Product Images NDC 0409-0182
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 0409-0182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Gemcitabine 02)
The text provides information about progression-free probability in a medical study comparing the drugs Gemcitabine and Carboplatin. The study involved 178 patients and shows that the median progression-free survival for Gemcitabine/Carboplatin was 8.6 months compared to 5.8 months for Carboplatin alone. The study found a p-value of 0.0038, suggesting the difference in survival rates between the two drugs is statistically significant. Additionally, the provided graph shows the progression-free survival over a period of 24 months.*
Figure 2 (Gemcitabine 03)
This is a comparison of the progression-free probability of two treatments for documented disease progression. The first is a combination of Gemcitabine and Pacitaxel, and the second is only Paciitaxel. The median time for the combination treatment is 5.2 months, while for Pacitaxel only, it is 2.9 months. The significance level of this result is p <0.0001, indicating a statistically significant difference between the treatments. The graph shows time to documented disease progression in months for each treatment.*
Figure 3 (Gemcitabine 04)
Figure 4 (Gemcitabine 05)
The given text represents a chart that has two cancer treatment options, 5-FU and Gemcitabine, on the x-axis and fraction surviving percentages on the y-axis. The chart is also depicting the survival time in months (8, 12, and 16) at which the treatment is given to the patients.*
Logo (Gemcitabine 06)
Principal Display Panel (1 g/26.3 mL Vial Label)
Principal Display Panel (1 g/26.3 mL Vial Carton)
Gemcitabine Injection is a cytotoxic injection used for intravenous use. The injection is stored in 263mL single-dose vials which must be diluted before use. Each vial contains 1g of gemcitabine with water for injection. The pH level is adjusted using hydrochloric acid and/or sodium hydrovide. The drug is distributed by Hospira Inc, Lake Forest, IL. It is essential to exercise great caution while using the drug to prevent inhaling particles and exposing the skin to it. No other information is readable from the given text.*
Principal Display Panel (200 mg/5.26 mL Vial Label)
Principal Display Panel (200 mg/5.26 mL Vial Carton)
Gemcitabine is a potentially cytotoxic agent used for injection. Each vial contains 200mg gemcitabine and water for injection. Hydrochloric acid and/or sodium hydroxide may be added for pH adjustment. Gemcitabine is highly toxic and care should be taken to prevent inhaling particles and exposing the skin to it. The drug must be diluted prior to intravenous use, and unused portion should be discarded. The drug is distributed by Hospira, Inc.*
Principal Display Panel (2 g/52.6 mL Vial Label)
Principal Display Panel (2 g/52.6 mL Vial Carton)
This is a description of a medication called Gemcitabine Injection, which comes in a 2g vial of gemcitabine and Water for Injection, USP. It is a cytotoxic agent that must be diluted before intravenous use, and should be stored between 2 and 8°C. The pH may be adjusted using hydrochloric acid, NF and/or sodium hydroxide, NF. Caution should be taken not to inhale particles or expose skin to the drug. The medication is distributed by Hospira, Inc. in Lake Forest, IL, USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
